TABLE 2.

Effects of Targeted Therapy After Bronchoscopic Phenotyping of Severe Asthma Patients

	Gastroesophageal Reflux	Subacute Bacterial Infection	Tissue Eosinophilia	Combination	Nonspecific
ACT score prebronchoscopy	10.0 ± 3.4	12.8 ± 3.7	9.5 ± 3.5	11.7 ± 4.3	15.0 ± 4.9
ACT score postbronchoscopy	17.5 ± 4.3*	19.9 ± 3.7*	17.0 ± 5.6†	19.2 ± 3.8*	17.5 ± 3.4NS
FEV1 % predicted prebronchoscopy	61.5 ± 16.1	63.8 ± 18.3	46.8 ± 11.8	53.0 ± 13.4	59.6 ± 24.8
FEV1 % predicted postbronchoscopy	75.9 ± 15.3‡	79.0 ± 14.5‡	76.6 ± 5.5§	67.5 ± 13.8‡	68.5 ± 21.5NS

Prebronchoscopy data were obtained while patients were on standard therapy and postbronchoscopy values were measured after 12 to 60 weeks of targeted phenotype-specific therapy.

ACT indicates asthma control test; NS, not significant.

^*P ≤ 0.0005,

^†≤ 0.02,

^ಠ0.0004, and

^§≤ 0.003.

Adapted from Good et al.²⁷ Adaptations are themselves works protected by copyright. So in order to publish this adaptation, authorization must be obtained both from the owner of the copyright in the original work and from the owner of copyright in the translation or adaptation.